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Abstract Bioengineered by ectopic expression of stemness
factors, induced pluripotent stem (iPS) cells demonstrate
embryonicstemcell-likepropertiesandofferauniqueplatform
for derivation of autologous pluripotent cells from somatic
tissue sources. In the process of nuclear reprogramming,
somatictissuesareconvertedtoapluripotentgroundstate,thus
unlocking an unlimited potential to expand progenitor pools.
Moleculardissectionofnuclearreprogrammingsuggeststhata
residual memory derived from the original parental source,
along with the remnants of the reprogramming process itself,
leads to a biased potential of the bioengineered progeny to
differentiateintotargettissuessuchascardiaccytotypes.Inthis
way, iPS cells that fulfill pluripotency criteria may display
heterogeneous profiles for lineage specification. Small
molecule-based strategies have been identified that modulate
the epigenetic state of reprogrammed cells and are opti-
mized to erase the residual memory and homogenize the
differentiation potential of iPS cells derived from distinct
backgrounds. Here, we describe the salient components of
the reprogramming process and their effect on the down-
stream differentiation capacity of the iPS populations in the
context of cardiovascular regenerative applications.
Keywords iPS.Epigenetic memory.Differentiation
capacity.Memory-free pluripotency
Introduction
Pluripotent cells have the capacity of differentiating
towards cell types from the three germinal layers of the
body while holding a high replication potential. In this way,
embryonic stem cells derived in the 1980s (mouse) [1] and
1990s (human) [2] revolutionized biomedical research,
offering the possibility to produce de novo tissues that
could be used to replace or regenerate diseased organs;
however, ethical concerns and host/donor immunological
mismatch have contributed to the hurdles that challenge
clinical applications.
A paradigm shift within the field of regenerative
medicine occurred in 2006 with the derivation of pluripo-
tent cells from somatic fibroblasts by transduction with a
set of four transcription factors [3]. Uniquely, this platform
eliminates the need for embryonic tissue and opens a new
avenue for personalized drug testing, diagnosis, and therapy
[4, 5]. Studies that followed have optimized the derivation
of induced pluripotent stem (iPS) cells from human somatic
sources [6–13] and have refined this process to increase
reprogramming efficiency [14–17]. Also, numerous proto-
cols have been described to guide differentiation of these
bioengineered pluripotent cells into diverse cell types useful
for broad applications in discovery and translational science
[18–26]. Notably, specialized cardiovascular lineages de-
rived through the process of nuclear reprogramming of
healthy and/or diseased somatic tissues have been applied
across the continuum of biomedical applications [27–30].
The opportunity to refine tissue-specific differentiation
protocols by identifying the appropriate somatic tissue source
and reprogramming strategy would accelerate the field of
cardiovascular regenerative biology. Based on the epigenetic
and transcriptional carryover that follows reprogramming, a
residual memory may be influenced by both tissue of origin
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DOI 10.1007/s12265-010-9250-2[31] and the reprogramming process [32, 33]. The impact of
thismemorywilllikelybedependent onthe use orapplication
of the bioengineered iPS cells while understanding the
determinants of residual memory may lead to targeted
optimization of the reprogramming process.
Tissue of Origin
Original studies on nuclear reprogramming by viral
transduction utilized murine embryonic fibroblasts [3, 34,
35], a cell commonly used in stem cell biology, to
bioengineer a pluripotent state from a somatic cytotype;
however, the embryonic origin of these cells raised the
possibility for contamination with pluripotent progenitors
rather than bona fide reprogramming [36]. This scientific
uncertainty was addressed by applying adult fibroblasts as
alternative starting material to generate pluripotent stem
cells [37]. These somatic cells were also amenable to
reprogramming, demonstrating that pluripotent ground state
can be reset in adult-derived cells that were previously fully
committed to a defined phenotype [38]. A broad array of cell
types have subsequently been used as tissue source, including
other adult somatic tissues such as dermal skin [39, 40], liver/
stomach biopsy [41], beta cells from the pancreas [42], as
well as neural [43, 44], and hematopoietic cells [45]. The
possibility of reprogramming somatic cells derived from
different starting tissues at similar efficiency rates would
support a stochastic model in which reprogramming a
pluripotent state was limited by time and not inherent to
the starting cell type [46]. In this way, all donor cells,
regardless of their tissue origin, eventually could be reset to
the pluripotent state upon continuous overexpression of
stemness-related genes. This finding, in contrast to an elite
model that suggests that only a specific subpopulation of
progenitor cells could be completely reprogrammed [47],
indicated that differentiation is a fully reversible process;
however, it has also been shown that distinct tissue types
have various bioengineering requirements to ensure full
reprogramming towards the pluripotent ground state. A case
in point, stomach epithelium and hepatocytes require lower
levels of reprogramming factors to achieve pluripotency, thus
offering an advantage to bioengineer ectopic expression with
alternative delivery strategies [41].
Despite the “universal” reprogramming theory that
enables a wide pool of starting cell sources, comparison
of reprogrammed pluripotent cells derived from distinct
tissues unmasked differences in the in vivo differentiation
and growth capacity. In this regard, mouse adult tail tip
fibroblasts and adult hepatocytes have demonstrated the
highest risk of dysregulated teratoma formation when
injected into immunodeficient mice in contrast to iPS cells
derived from embryonic fibroblasts or stomach epithelium
characterized by a lower teratogenic propensity similar to
embryonic stem cells [48]. Thus, residual molecular
profiles, inherent to source tissue, do apparently determine
the phenotypic outcome upon in vivo transplantation into a
permissive environment.
In human cells, successful reprogramming has also been
possible using several starting tissue sources that include,
beyond dermal skin [6, 7], keratinocytes [8], adipose tissue
[9], and peripheral blood [10–13]. Furthermore, nuclear
reprogramming by transcription factor transduction has been
used to obtain pluripotent cells derived from patients. iPS
cells have been generated from both genetic and non-
inheritable diseases, including Parkinson’s disease, Duchenne
muscular dystrophy, Becker’s muscular dystrophy, Down’s
syndrome, Huntington’s disease [49], myeloproliferative
disorders [50], amyotrophic lateral sclerosis [51], Fanconi’s
anemia [52], type 1 diabetes [23], spinal muscular atrophy
[53], familial dysautonomia [54], LEOPARD syndrome [27],
and long QT syndrome [28]. In cardiovascular applications,
patient-specific iPS cells have been used to identify
molecular causes of disease deepening our understanding of
various cardiac syndromes and demonstrating the usefulness
of this platform as a translational discovery tool. In particular,
long QT syndrome patient dermal fibroblasts have been
reprogrammed and subsequently differentiated into cardio-
myocytes that were shown to display characteristic pheno-
types recapitulating molecular features of the disease [28]. A
detailed characterization and comparison with cells derived
from healthy relatives led to significant discoveries regarding
the molecular causes of this disease and allowed for
therapeutic protective drug testing in vitro [28]. In a similar
way, molecular features of hypertrophic cardiomyopathy
found in patients with LEOPARD syndrome have also been
recapitulated in vitro using iPS cells coupled with cardiac
differentiation protocols [27]. Therefore, iPS cell technology
permits patient-specific and in vitro studies not possible from
other sources of primary human cells [27, 28].
Therapeutic application of iPS cells has also been
tested in cardiac disease revealing the capacity to rescue
morphological and functional physiological parameters in
vivo in a model of acute ischemic injury to the
myocardium [29]. In fact, reprogrammed cells injected
at the site of infarction show engraftment for several
weeks together with physical and physiological integra-
tion within the host tissue [29]. Cells corresponding to all
three cardiac lineages (cardiomyocytes, smooth muscle,
and endothelium) can be derived from the injected iPS
cells, contributing to a reduced fibrotic scar as well as to
the recovery of the functional parameters representative of
cardiac performance [29]. Therefore, reprogramming
somatic cells into functional pluripotent stem cells
demonstrates the ability to produce cardiac regeneration
from ordinary tissue sources [29].
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consistently demonstrated the cardiac differentiation poten-
tial of iPS cells in vitro (Table 1). Beyond first approxima-
tion of gene expression, structural characterization and
beating activity originally used as landmarks of cardiac
differentiation [20, 21, 29, 55, 56], functional parameters
such as electrophysiological characterization, force meas-
urements, and drug regulation have emerged as a critical
component defining the cardiogenic potential of iPS cells
[57–64].
The application of iPS technology as a tissue-specific
discovery platform, diagnostic tool, or therapeutic agent
highlights the importance of reproducible cardiac differen-
tiation. Notably, the original tissue in which nuclear
reprogramming is performed influences the differentiation
potential of the resulting iPS product (Fig. 1). Initially,
Marchetto et al. [65] described how neural stem cells that
had been reprogrammed to fulfill pluripotency criteria (e.g.,
in vitro differentiation and in vivo teratoma formation)
displayed incomplete suppression of neural-specific genes
and partial induction of early embryonic genes. These
results were confirmed by Ghosh et al. in an extended array
of human reprogrammed cells derived from fetal or
newborn fibroblasts, adipose stem cells, and keratinocytes,
each of them maintaining a transcriptional memory
corresponding to the tissue of origin [66]. Upregulation of
lineage-specific genes in the ground state predicted possible
downstream effects on the differentiation capacities of the
bioengineered iPS lines. This observation was confirmed
when mesoderm reprogrammed cells were shown to give
rise to osteogenic cells more efficiently than blood-derived
iPS cells, thereby yielding additional hematopoietic colo-
nies [32]. Therefore, somatic cells reprogrammed by
transcription factor induction favorably differentiate along
lineages related to the donor cell (Fig. 1)[ 32]. DNA
methylation patterns in promoter regions and histone
acetylation, both components of the epigenetic state of the
cell, have been shown to correlate with the propensity of
differentiation after reprogramming adding epigenetic
memory as an important level of regulation in the
bioengineering process [31, 32]. Furthermore, the transcrip-
tional fingerprint of iPS cells derived from distinct origins
reveals gene expression patterns characteristic of the
original cell source [31]. In an attempt to erase residual
epigenetic and transcriptional memories from bioengi-
neered pluripotent cells, two methods have been described.
According to Polo et al. and in agreement with previous
work describing reprogramming as a process that continues
in vitro for several passages [33], continuous cell division
resolves transcriptional and epigenetic differences equili-
brating the differentiation capacity of iPS cells derived from
different tissue sources [31] (Fig. 1). In adifferentapproach,
Kim et al. used epigenetic modifiers to homogenize
differentiation capacities from iPS cells with various origins
[32] (Fig. 1). Therefore, the residual memory of source
cytotype is not permanent and epigenetic modification can
provide an effective strategy to alter the differentiation
capacity of reprogrammed stem cells.
Since cells demonstrated to be pluripotent by current
standards may display dissimilarities in a subsequent
differentiationcapacity,propensityforlineagespecification
may be required to accurately predict the extent of nuclear
reprogramming. Whether preferential differentiation ca-
pacity is an advantage or a detriment depends on the
Table 1 Multimodal characterization of cardiac differentiation potential of iPS cells
Tissue source Gene
expression
IF FACS Ultra-structure Patch
clamp
Calcium
imaging
MEA Pharmacol
response
In vivo
chimerism
In situ
contribution
Ref. no.
Mouse fibroblast √√ √ √ [57]
Mouse fibroblast √√ √ √ √ √ [58]
Mouse fibroblast √√ √ √ [59]
Mouse fibroblast √√ √ √ √ [60]
Mouse and human
fibroblast
√√ √ [55]
Mouse fibroblast √√ √ √ [20]
Mouse fibroblast √√ √√ [29]
Mouse fibroblast √√ √ √ [61]
Mouse fibroblast √√ √ √ [21]
Human fibroblast √√ √ √ [56]
Human fibroblast √√ √ √ [62]
Human fibroblast √√ √ [63]
Human fibroblast √√ √ √ [64]
IF immunofluorescence, FACS fluorescence activated cell sorting, MEA multielectrode array, Pharmacol pharmacological
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to obtain in vitro, the impact of residual memory may benefit
subsequent derivation of differentiated tissues if iPS cells are
derived from related cell types. On the other hand, standard-
ization of pluripotency will be required for basic biological
applications or when a non-related tissue of origin is
bioengineered in order to obtain a defined cytotype. In
summary,tissueoforiginmaybiasthedifferentiationpotential
of iPS cells due to residual transcriptional and epigenetic
memories that are latent in the pluripotent ground state.
Reprogramming Strategy
Exogenous Transgenes
Distilling down from an array of pluripotency-related
genes, four factors were initially demonstrated to be
sufficient to re-establish the ground state upon transduction
in mouse somatic cells [3]. A slightly different combination
was later shown to work in human cells, with two of the
factors being maintained as a core (namely Sox2 and Oct4)
and two different transcription factors being interchange-
able (either Klf4 and c-Myc or Lin28 and Nanog) [7]. With
refinement of the protocols, the oncogene c-Myc, was
recognized to be dispensable [40] or replaceable by another
family member, low transformation capacity L-Myc, limit-
ing the oncogenicity of the derived iPS cells [67]. In an
attempt to minimize the number of required factors, small
molecules have been assayed for downstream effects
involved in the ground state resetting process. Notably,
specific cell types with high intrinsic expression levels of
stemness factors have been used in an attempt to simplify
the reprogramming process [68]. The most dramatic
example has been the reprogramming of neural cells with
only Oct4 [69]. Thus, a targeted strategy to minimize the
burden of ectopic transgenes is devised by complementing
the factors required for reprogramming iPS cells.
Regardless of the specific factors used in this induction
of undifferentiated phenotype, sustained expression has
been shown to be necessary for a limited time, reprog-
rammed cells becoming independent of exogenous trans-
genes a few weeks following transduction [70]. Depending
on the expression platform utilized to initiate nuclear
reprogramming, persistent expression of stemness factors
may be responsible for unintentional secondary effects. In
this regard, in vitro endodermal differentiation in the
presence of the reprogramming factors beyond the pluripo-
tency induction process has been shownto be impaired when
compared to reprogrammed cells from which exogenous
transgenes had been excised [71]. Indeed, parental iPS cells
containing a polycistronic vector that encoded the four
reprogramming factors showed a diminished capacity to
respond to soluble growth factor–differentiation cues while
their transgene-free progeny responded to the same protocol
upregulating key endodermal transcription factors [71]. A
similar outcome was observed for ectoderm and mesoderm
tissue, in both cases revealing that differentiation was
enhanced by excision of the reprogramming factors [71].
Indeed, a single factor of the bioengineering kit might
have a significant effect on the differentiation capacity of
iPS cells. In particular, the presence of the oncogene c-Myc
during the reprogramming process impairs cardiac differ-
entiation capacity in bioengineered pluripotent cells [59]
while the absence of this factor leads to reprogrammed
progeny with a high cardiogenic propensity indicated by
Memory-free 
pluripotent cells 
Pluripotent cells with 
residual memory 
Biased differentiation  Unbiased differentiation
Reprogramming 
Passaging 
Epigenetic 
modulators 
Tissue of origin 
Fig. 1 Strategies to standardize
the differentiation capacity of
reprogrammed cells. Residual
epigenetic and transcriptional
memories cause bioengineered
progeny to have a biased differ-
entiation propensity, indepen-
dent of acquired pluripotency
as defined by sporadic three
germ layer differentiation
capacity. Strategies that include
continuous passaging or treat-
ment with epigenetic modulators
are sufficient to erase cellular
memory of the somatic cell
origin and ensure unbiased
differentiation capacity of
bioengineered iPS cells
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sarcomeric structures, calcium currents, spontaneous beat-
ing activity, and high cardiac gene expression [58]. An
insight into the underlying mechanism has been obtained
using trichostatin A, a histone deacetylase inhibitor, which
facilitated myocardial differentiation despite c-Myc expo-
sure in an iPS line showing low levels of cardiac gene
expression and beating activity prior to treatment [72]. This
study reinforces the importance of the epigenetic acetylation
state as a component of the residual memory. Considering
the data shown in this report, the reprogramming strategy
may have an epigenetic imprint that modulates down-
stream differentiation properties. Another explanation
would be the repression exerted by Myc on endoderm
differentiation pathways that are requited for proper
mesoderm differentiation [73]. According to this study, c-
Myc inhibits primitive endoderm specification by repres-
sing Gata6 at the transcriptional level impacting down-
stream differentiation events linked to mesoderm formation.
In summary, exposure and combination of exogenous
transgenes used for pluripotency induction may have a
direct or indirect effect on the differentiation potential of
the bioengineered progeny.
Facilitators of Reprogramming
Designing a complementary strategy to optimize the rate-
limiting steps of nuclear reprogramming not only offers
advantages for the overall efficiency of iPS derivation but
has an influence on the quality and differentiation potential
of the reprogrammed cells [32, 74]. Facilitators are small
molecules or conditions that improve the efficacy of nuclear
reprogramming. An example of a condition favoring
bioengineering is hypoxia. Decreasing oxygen levels to
5% creates an environment that provokes a complex re-
arrangement of gene expression profile leading to increased
induction of reprogramming in human fibroblasts [15].
Important to the epigenetic state, histone acetylation
and methylation regulate the accessibility of the transcrip-
tion machinery to the genetic blueprint within the parental
cell. In this context, inhibition of histone deacetylase or
DNA-methyl transferase using epigenetic modifiers val-
proic acid (VPA) or 5-aza-cytidine (5-AZA) has benefited
the chromatin remodeling and increased the efficiency of
standardized reprogramming protocols [16, 17]. Charac-
terization of the epigenetic state has revealed a fundamen-
tal component in determining the fate of bioengineered
cells. This has led to the use of epigenetic modulators such
as VPA, 5-AZA, or trichostatin A to revert repressive
residual epigenetic memory in order to increase the range
and reproducibility of tissues derived from a reprog-
rammed line, homogenizing and improving differentiation
potential [32, 72].
Conclusion
Together, these observations lead to the hypothesis that
beyond induction of the pluripotency state, the differentiation
properties of the engineered cells also need to be carefully
characterized and, if needed, standardized. Residual memory
retained from the original cell source should be considered as
a possible limitation for broad differentiation profiles,
although it could also be a useful feature when the tissue of
interest or a closely related one is readily accessible.
Optimized reprogramming strategies may resolve the persis-
tent effects due to residual transgene expression while
strategies such as continuous passaging and use of epigenetic
modulators may be useful to homogenize differentiation
capacity despite the tissue of origin used for iPS cell
production. Collectively, nuclear reprogramming strategies
designed to achieve both functional pluripotency while
promoting tissue-specific predilections will continue to
accelerate the focused effort of discovery, translation, and
applications for specialized fields such as cardiovascular
regenerative medicine.
Acknowledgments Work in the laboratory of the authors was
supported by the National Institutes of Health, Marriott Individualized
Medicine Program, Marriott Heart Disease Research Program, and
Mayo Clinic.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Martin, G. R. (1981). Isolation of a pluripotent cell line from early
mouse embryos cultured in medium conditioned by teratocarci-
noma stem cells. Proceedings of the National Academy of
Sciences of the United States of America, 78, 7634–7638.
2. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M.
A., Swiergiel, J. J., Marshall, V. S., et al. (1998). Embryonic stem
cell lines derived from human blastocysts. Science, 282, 1145–
1147.
3. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent
stem cells from mouse embryonic and adult fibroblast cultures by
defined factors. Cell, 126, 663–676.
4. Terzic, A., & Nelson, T. J. (2010). Regenerative medicine
advancing health care 2020. Journal of the American College of
Cardiology, 55, 2254–2257.
5. Nelson, T. J., Behfar, A., Yamada, S., Martinez-Fernandez, A., &
Terzic, A. (2009). Stem cell platforms for regenerative medicine.
Clinical and Translational Science, 2, 222–227.
6. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T.,
Tomoda, K., et al. (2007). Induction of pluripotent stem cells from
adult human fibroblasts by defined factors. Cell, 131, 861–872.
7. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J.,
Frane, J. L., Tian, S., et al. (2007). Induced pluripotent stem cell
lines derived from human somatic cells. Science, 318, 1917–1920.
J. of Cardiovasc. Trans. Res. (2011) 4:131–137 1358. Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A.,
Gonzalez, F., et al. (2008). Efficient and rapid generation of
induced pluripotent stem cells from human keratinocytes. Nature
Biotechnology, 26, 1276–1284.
9. Sun, N., Panetta, N. J., Gupta, D. M., Wilson, K. D., Lee, A., Jia,
F., et al. (2009). Feeder-free derivation of induced pluripotent
stem cells from adult human adipose stem cells. Proceedings of
the National Academy of Sciences of the United States of America,
106, 15720–15725.
10. Loh, Y. H., Agarwal, S., Park, I. H., Urbach, A., Huo, H., Heffner,
G. C., et al. (2009). Generation of induced pluripotent stem cells
from human blood. Blood, 113, 5476–5479.
11. Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., et
al. (2010). Generation of induced pluripotent stem cells from human
terminallydifferentiated circulatingTcells.Cell Stem Cell, 7,1 1 –14.
12. Staerk, J., Dawlaty, M. M., Gao, Q., Maetzel, D., Hanna, J.,
Sommer, C. A., et al. (2010). Reprogramming of human
peripheral blood cells to induced pluripotent stem cells. Cell Stem
Cell, 7,2 0 –24.
13. Loh, Y. H., Hartung, O., Li, H., Guo, C., Sahalie, J. M., Manos, P.
D., et al. (2010). Reprogramming of T cells from human
peripheral blood. Cell Stem Cell, 7,1 5 –19.
14. Mali,P.,Chou,B.K.,Yen,J.,Ye,Z.,Zou,J.,Dowey,S.,etal.(2010).
Butyrate greatly enhances derivation of human induced pluripotent
stem cells by promoting epigenetic remodeling and the expression of
pluripotency-associated genes. Stem Cells, 28,7 1 3 –720.
15. Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., & Yamanaka,
S. (2009). Hypoxia enhances the generation of induced pluripotent
stem cells. Cell Stem Cell, 5, 237–241.
16. Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M.,
Chen, A. E., et al. (2008). Induction of pluripotent stem cells by
defined factors is greatly improved by small-molecule com-
pounds. Nature Biotechnology, 26, 795–797.
17. Mikkelsen, T. S., Hanna, J., Zhang, X., Ku, M., Wernig, M.,
Schorderet, P., et al. (2008). Dissecting direct reprogramming
through integrative genomic analysis. Nature, 454,4 9 –55.
18. Tashiro, K., Inamura, M., Kawabata, K., Sakurai, F., Yamanishi,
K., Hayakawa, T., et al. (2009). Efficient adipocyte and osteoblast
differentiation from mouse induced pluripotent stem cells by
adenoviral transduction. Stem Cells, 27, 1802–1811.
19. Niwa, A., Umeda, K., Chang, H., Saito, M., Okita, K., Takahashi,
K., et al. (2009). Orderly hematopoietic development of induced
pluripotent stem cells via flk-1(+) hemoangiogenic progenitors.
Journal of Cellular Physiology, 221, 367–377.
20. Narazaki, G., Uosaki, H., Teranishi, M., Okita, K., Kim, B.,
Matsuoka, S., et al. (2008). Directed and systematic differentiation
of cardiovascular cells from mouse induced pluripotent stem cells.
Circulation, 118, 498–506.
21. Schenke-Layland, K., Rhodes, K. E., Angelis, E., Butylkova, Y.,
Heydarkhan-Hagvall, S., Gekas, C., et al. (2008). Reprogrammed
mouse fibroblasts differentiate into cells of the cardiovascular and
hematopoietic lineages. Stem Cells, 26, 1537–1546.
22. Senju, S., Haruta, M., Matsunaga, Y., Fukushima, S., Ikeda, T.,
Takahashi, K., et al. (2009). Characterization of dendritic cells and
macrophages generated by directed differentiation from mouse
induced pluripotent stem cells. Stem Cells, 27, 1021–1031.
23. Maehr, R., Chen, S., Snitow, M., Ludwig, T., Yagasaki, L.,
Goland, R., et al. (2009). Generation of pluripotent stem cells
from patients with type 1 diabetes. Proceedings of the National
Academy of Sciences of the United States of America, 106,
15768–15773.
24. Song, Z., Cai, J., Liu, Y., Zhao, D., Yong, J., Duo, S., et al.
(2009). Efficient generation of hepatocyte-like cells from human
induced pluripotent stem cells. Cell Research, 19, 1233–1242.
25. Buchholz, D. E., Hikita, S. T., Rowland, T. J., Friedrich, A. M.,
Hinman, C. R., Johnson, L. V., et al. (2009). Derivation of
functional retinal pigmented epithelium from induced pluripotent
stem cells. Stem Cells, 27, 2427–2434.
26. Karumbayaram, S., Novitch, B. G., Patterson, M., Umbach, J. A.,
Richter, L., Lindgren, A., et al. (2009). Directed differentiation of
human-induced pluripotent stem cells generates active motor
neurons. Stem Cells, 27, 806–811.
27. Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y. S.,
Schaniel, C., Lee, D. F., et al. (2010). Patient-specific induced
pluripotent stem-cell-derived models of LEOPARD syndrome.
Nature, 465, 808–812.
28. Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-
Flügel, L., et al. (2010). Patient-specific induced pluripotent stem-
cell models for Long-QT Syndrome. The New England Journal of
Medicine, 363, 1397–1409.
29. Nelson, T. J., Martinez-Fernandez, A., Yamada, S., Perez-Terzic,
C., Ikeda, Y., & Terzic, A. (2010). Repair of acute myocardial
infarction by human stemness factors induced pluripotent stem
cells. Circulation, 120, 408–416.
30. Nelson, T. J., Martinez-Fernandez, A., & Terzic, A. (2010).
Induced pluripotent stem cells: developmental biology to regen-
erative medicine. Nature Reviews Cardiology, 7, 700–710.
31. Polo, J. M., Liu, S., Figueroa, M. E., Kulalert, W., Eminli, S., Tan,
K. Y., et al. (2010). Cell type of origin influences the molecular
and functional properties of mouse induced pluripotent stem cells.
Nature Biotechnology, 28, 848–855.
32. Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., et al.
(2010). Epigenetic memory in induced pluripotent stem cells.
Nature, 467, 285–290.
33. Chin, M. H., Mason, M. J., Xie, W., Volinia, S., Singer, M.,
Peterson, C., et al. (2009). Induced pluripotent stem cells and
embryonic stem cells are distinguished by gene expression
signatures. Cell Stem Cell, 5, 111–123.
34. Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of
germline-competent induced pluripotent stem cells. Nature, 448,
313–317.
35. Boland, M. J., Hazen, J. L., Nazor, K. L., Rodriguez, A. R.,
Gifford, W., Martin, G., et al. (2009). Adult mice generated from
induced pluripotent stem cells. Nature, 461,9 1 –94.
36. Cyranoski, D. (2008). Stem cells: 5 things to know before
jumping on the iPS bandwagon. Nature, 452, 406–408.
37. Meissner, A., Wernig, M., & Jaenisch, R. (2007). Direct
reprogrammingofgeneticallyunmodifiedfibroblastsintopluripotent
stem cells. Nature Biotechnology, 25, 1177–1181.
38. Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C.,
Wernig, M., et al. (2008). Direct reprogramming of terminally
differentiated mature B lymphocytes to pluripotency. Cell, 133,
250–264.
39. Hanna, J., Wernig, M., Markoulaki, S., Sun, C. W., Meissner, A.,
Cassady, J. P., et al. (2007). Treatment of sickle cell anemia mouse
model with ips cells generated from autologous skin. Science,
318, 1920–1923.
40. Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K.,
Ichisaka, T., Aoi, T., et al. (2008). Generation of induced
pluripotent stem cells without myc from mouse and human
fibroblasts. Nature Biotechnology, 26, 101–106.
41. Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K.,
Takahashi, K., et al. (2008). Generation of pluripotent stem cells
from adult mouse liver and stomach cells. Science, 321, 699–702.
42. Stadtfeld, M., Brennand, K., & Hochedlinger, K. (2008).
Reprogramming of pancreatic beta cells into induced pluripotent
stem cells. Current Biology, 18, 890–894.
43. Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T.
W., & Smith, A. (2009). Promotion of reprogramming to ground
state pluripotency by signal inhibition. PLoS Biology, 6, e253.
44. Kim, J. B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano,
V., et al. (2009). Pluripotent stem cells induced from adult neural
136 J. of Cardiovasc. Trans. Res. (2011) 4:131–137stem cells by reprogramming with two factors. Nature, 454, 646–
650.
45. Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T.,
Mostoslavsky, G., et al. (2009). Differentiation stage determines
potential of hematopoietic cells for reprogramming into induced
pluripotent stem cells. Nature Genetics, 41, 968–976.
46. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J.,
Creyghton, M. P., et al. (2009). Direct cell reprogramming is a
stochastic process amenable to acceleration. Nature, 462, 595–
601.
47. Byrne, J. A., Nguyen, H. N., & Reijo Pera, R. A. (2009).
Enhanced generation of induced pluripotent stem cells from a
subpopulation of human fibroblasts. PLoS ONE, 4, e7118.
48. Miura, K., Okada, Y., Aoi, T., Okada, A., Takahashi, K., Okita,
K., et al. (2009). Variation in the safety of induced pluripotent
stem cell lines. Nature Biotechnology, 27, 743–745.
49. Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T.,
Shimamura, A., et al. (2008). Disease-specific induced pluripotent
stem cells. Cell, 134, 877–886.
50. Ye, Z., Zhan, H., Mali, P., Dowey, S., Williams, D. M., Jang, Y.
Y., et al. (2009). Human induced pluripotent stem cells from blood
cells of healthy donors and patients with acquired blood disorders.
Blood, 114, 5473–5480.
51. Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M.,
Mitsumoto, H., Chung, W., et al. (2008). Induced pluripotent stem
cells generated from patients with als can be differentiated into
motor neurons. Science, 321, 1218–1221.
52. Raya, A., Rodriguez-Piza, I., Guenechea, G., Vassena, R.,
Navarro, S., Barrero, M. J., et al. (2009). Disease-corrected
haematopoietic progenitors from fanconi anaemia induced pluripo-
tent stem cells. Nature, 460,5 3 –59.
53. Ebert, A. D., Yu, J., Rose, F. F., Jr., Mattis, V. B., Lorson, C. L.,
Thomson, J. A., et al. (2009). Induced pluripotent stem cells from
a spinal muscular atrophy patient. Nature, 457, 277–280.
54. Lee, G., Papapetrou, E. P., Kim, H., Chambers, S. M., Tomishima,
M. J., Fasano, C. A., et al. (2009). Modelling pathogenesis and
treatment of familial dysautonomia using patient-specific ipscs.
Nature, 461, 402–406.
55. Moretti, A., Bellin, M., Jung, C. B., Thies, T. M., Takashima, Y.,
Bernshausen, A., et al. (2010). Mouse and human induced
pluripotent stem cells as a source for multipotent Isl1+ cardiovas-
cular progenitors. The FASEB Journal, 24, 700–711.
56. Gai, H., Leung, E. L., Costantino, P. D., Aguila, J. R., Nguyen, D.
M., Fink, L. M., et al. (2009). Generation and characterization of
functional cardiomyocytes using induced pluripotent stem cells
derived from human fibroblasts. Cell Biology International, 33,
1184–11893.
57. Kuzmenkin, A., Liang, H., Xu, G., Pfannkuche, K., Eichhorn, H.,
Fatima, A., et al. (2009). Functional characterization of cardio-
myocytes derived from murine induced pluripotent stem cells in
vitro. The FASEB Journal, 23, 4168–4180.
58. Martinez-Fernandez, A., Nelson, T. J., Yamada, S., Reyes, S.,
Alekseev, A. E., Perez-Terzic, C., et al. (2009). iPS programmed
without c-MYC yield proficient cardiogenesis for functional heart
chimerism. Circulation Research, 105, 648–656.
59. Martinez-Fernandez, A., Nelson, T. J., Ikeda, Y., & Terzic, A.
(2010). c-MYC independent nuclear reprogramming favors
cardiogenic potential of induced pluripotent stem cells. Journal
of Cardiovascular Translational Research, 3,1 3 –23.
60. Mauritz, C., Schwanke, K., Reppel, M., Neef, S., Katsirntaki, K.,
Maier, L. S., et al. (2008). Generation of functional murine cardiac
myocytes from induced pluripotent stem cells. Circulation, 118,
507–517.
61. Pfannkuche, K., Liang, H., Hannes, T., Xi, J., Fatima, A.,
Nguemo, F., et al. (2009). Cardiac myocytes derived from murine
reprogrammed fibroblasts: intact hormonal regulation, cardiac ion
channel expression and development of contractility. Cellular
Physiology and Biochemistry, 24,7 3 –86.
62. Yokoo, N., Baba, S., Kaichi, S., Niwa, A., Mima, T., Doi, H., et
al. (2009). The effects of cardioactive drugs on cardiomyocytes
derived from human induced pluripotent stem cells. Biochemical
and Biophysical Research Communications, 387, 482–488.
63. Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J.,
Palecek, S. P., et al. (2009). Functional cardiomyocytes derived
from human induced pluripotent stem cells. Circulation Research,
104, e30–e41.
64. Zwi, L., Caspi, O., Arbel, G., Huber, I., Gepstein, A., Park, I. H.,
et al. (2009). Cardiomyocyte differentiation of human induced
pluripotent stem cells. Circulation, 120, 1513–1523.
65. Marchetto, M. C., Yeo, G. W., Kainohana, O., Marsala, M., Gage,
F. H., & Muotri, A. R. (2009). Transcriptional signature and
memory retention of human-induced pluripotent stem cells. PLoS
ONE, 4, e7076.
66. Ghosh, Z., Wilson, K. D., Wu, Y., Hu, S., Quertermous, T., & Wu,
J. C. (2010). Persistent donor cell gene expression among human
induced pluripotent stem cells contributes to differences with
human embryonic stem cells. PLoS ONE, 5, e8975.
67. Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T., &
Yamanaka, S. (2010). Promotion of direct reprogramming by
transformation-deficient Myc. Proceedings of the National Acad-
emyofSciences ofthe United States ofAmerica,107, 14152–14157.
68. Lyssiotis, C. A., Foreman, R. K., Staerk, J., Garcia, M., Mathur,
D., Markoulaki, S., et al. (2009). Reprogramming of murine
fibroblasts to induced pluripotent stem cells with chemical
complementation of klf4. Proceedings of the National Academy
of Sciences, 106, 8912–8917.
69. Kim, J. B., Zaehres, H., Arauzo-Bravo, M. J., & Scholer, H. R.
(2009). Generation of induced pluripotent stem cells from neural
stem cells. Nature Protocols, 4, 1464–1470.
70. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., &
Yamanaka, S. (2008). Generation of mouse induced pluripotent
stem cells without viral vectors. Science, 322, 949–953.
71. Sommer, C. A., Gianotti Sommer, A., Longmire, T. A., Christodoulou,
C., Thomas, D. D., Gostissa, M., et al. (2009). Excision of
reprogramming transgenes improves the differentiation potential of
ips cells generated with a single excisable vector. Stem Cells, 28,
64–67.
72. Kaichi, S., Hasegawa, K., Takaya, T., Yokoo, N., Mima, T.,
Kawamura, T., et al. (2010). Cell line-dependent differentiation of
induced pluripotent stem cells into cardiomyocytes in mice.
Cardiovascular Research, 88, 314–323.
73. Smith, K. N., Singh, A. M., & Dalton, S. (2010). Myc represses
primitive endoderm differentiation in pluripotent stem cells. Cell
Stem Cell, 7, 343–354.
74. Shi, Y., Desponts, C., Do, J. T., Hahm, H. S., Schöler, H. R., &
Ding, S. (2008). Induction of pluripotent stem cells from mouse
embryonic fibroblasts by Oct4 and Klf4 with small-molecule
compounds. Cell Stem Cell, 3, 568–574.
J. of Cardiovasc. Trans. Res. (2011) 4:131–137 137